Last reviewed · How we verify
SCIO-469 and bortezomib
At a glance
| Generic name | SCIO-469 and bortezomib |
|---|---|
| Sponsor | Scios, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma (PHASE2)
- Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |